Healthcare
PepGen Inc.(PEPG)
Live Price
Offline$1.79
+5.29% today
1Y Change
+5.76%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $120.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +25.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PepGen Inc. (PEPG) is a Healthcare stock with a market cap of $120.00M and listed on NASDAQ. The stock last traded around $1.79 and up 5.8% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +25.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +25.6%, free cash flow +1.2% with operating margin 0.0% and ROIC -56.9%. Stock Foundry combines PEPG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +25.6%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -6.1% | -6.7% | -10.9% |
2026 Mar 4, 2026 | +32.5% | -18.6% | -7.0% | -74.3% |
2025 Nov 12, 2025 | +17.5% | -4.7% | +7.8% | +11.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PEPG
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PEPG Max Drawdown
-81.17%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PEPG and SPY.
Company Overview
PepGen Inc.
NASDAQ Global Select
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
- Leadership
- James G. McArthur
- IPO Date
- May 6, 2022
- Employees
- 79
- Street Address
- 245 Main Street
- Mailing
- Boston, MA, 02142
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 781-797-0979
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 0.5
Growth
- Revenue
- 0.0%
- EPS
- +25.6%
- Free Cash Flow
- +1.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -75.7%
- ROIC
- -56.9%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 11.94
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.